144
Views
0
CrossRef citations to date
0
Altmetric
Notes

Tirucallane-type triterpenoid from the stem bark of Chisocheton lasiocarpus and its cytotoxic activity against MCF-7 breast cancer cells

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 803-809 | Received 01 Sep 2022, Accepted 30 Oct 2022, Published online: 21 Nov 2022
 

Abstract

Chisocarpene A (1) is a new tirucallane-type triterpenoid together with odoratone (2) and 24-methylenecycloartanol (3), isolated from the stem bark of Chisocheton lasiocarpus. The chemical structures of compounds 1–3 were elucidated through a detailed analysis of their spectroscopic data (IR, MS, 1 D, and 2 D NMR). The isolated compounds were evaluated for cytotoxic activity against the MCF-7 breast cancer cell line using a resazurin-based assay. Compound 1 showed the most potent activity (IC50 26.56 ± 1.01 µM) and was two-fold more active than the positive control.

Acknowledgments

We thank to Mrs. Kansi Haikal and Ms. Nurul Fadhilah at the Central Laboratory, Universitas Padjadjaran, Indonesia for HRTOF-MS measurements and cytotoxic assay.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This investigation was financially supported by RKDU grant [No. 2203/UN6.3.1/PT.00/2022] by Nurlelasari from Universitas Padjadjaran and Academic Leadership Grant [No. 1959/UN6.3.1/PT.00/2022] by Unang Supratman.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.